Skip to main content
PMC home page
Applied Microbiology logoLink to Applied Microbiology
. 1971 Nov;22(5):891–898. doi: 10.1128/am.22.5.891-898.1971

Chemotherapeutic Evaluation of Clotrimazole [Bay b 5097, 1 (o-Chloro-α-α-Diphenylbenzyl) Imidazole] 1

J Allan Waitz 1, Eugene L Moss 1, Marvin J Weinstein 1
PMCID: PMC376440  PMID: 4943591

Abstract

Clotrimazole has a broad spectrum of activity against yeast and filamentous fungi in vitro and also in vivo when given orally or parenterally to experimentally infected mice and when administered orally or topically to infected guinea pigs. In vitro a distinct inoculum effect has been observed with a number of strains of Candida and Torulopsis; minimal inhibitory concentrations have tended to increase with increased incubation time. With prolonged incubation times, resistance can be developed to clotrimazole in vitro, but this resistance is readily reversible upon passage in drug-free broth. The degree of in vivo activity of clotrimazole against Candida depends on the severity of infection used. Orally it appears to be more effective when administered by gavage than when given mixed in the diet. Pretreatment with the agent may decrease its efficacy because of drug inactivation. Against dermatophytes, clotrimazole has a degree of activity similar to griseofulvin when given orally, but it is less active than tolnaftate topically in cutaneous infection of Trichophyton mentagrophytes in guinea pigs. In vitro, but not in vivo, some gram-positive and gram-negative bacteria are inhibited by low concentrations of clotrimazole.

Full text

PDF
893

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Marget W., Adam D. Erste Erfahrungen mit dem Breitbandantimykotikum BAY b 5097. Med Klin. 1969 Jul 4;64(27):1235–1238. [PubMed] [Google Scholar]
  2. Oberste-Lehn H., Baggesen I., Plempel M. Erste klinische Erfahrungen bei System-Mykosen mit einem neuen oralen Antimykotikum. Dtsch Med Wochenschr. 1969 Jun 27;94(26):1365–passim. doi: 10.1055/s-0028-1111224. [DOI] [PubMed] [Google Scholar]
  3. Plempel M., Bartmann K., Büchel K. H., Regel E. BAY b 5097, a new orally applicable antifungal substance with broad-spectrum activity. Antimicrob Agents Chemother (Bethesda) 1969;9:271–274. [PubMed] [Google Scholar]
  4. Plempel M., Bartmann K., Büchel K. H., Regel E. Experimentelle Befunde über ein neues, oral wirksames Antimykotikum mit breiten Wirkungsspektrum. Dtsch Med Wochenschr. 1969 Jun 27;94(26):1356–passim. doi: 10.1055/s-0028-1111223. [DOI] [PubMed] [Google Scholar]
  5. Shadomy S. In vitro antifungal activity of clotrimazole (Bay b 5097). Infect Immun. 1971 Aug;4(2):143–148. doi: 10.1128/iai.4.2.143-148.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Shadomy S. In vivo studies with Bay b 5097. Antimicrob Agents Chemother (Bethesda) 1970;10:169–174. [PubMed] [Google Scholar]
  7. Waitz J. A., Moss E. L., Jr 'Prophylactic' activity of tolnaftate in experimental Trichophyton mentagrophytes infections of guinea pigs. Chemotherapy. 1969;14(3):170–175. doi: 10.1159/000220626. [DOI] [PubMed] [Google Scholar]
  8. Waitz J. A., Moss E. L., Jr, Oden E. M., Weinstein M. J. Biological activity of megalomicin, a new Micromonospora-produced macrolide antibiotic complex. J Antibiot (Tokyo) 1969 Jun;22(6):265–272. doi: 10.7164/antibiotics.22.265. [DOI] [PubMed] [Google Scholar]

Articles from Applied Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES